Shanghai Junshi Biosciences Co., a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Curon Biopharmaceutical (Curon), a privately held biotechnology company, &nb...
Merck Life Science in India announced the signing of a Memorandum of Understanding (MoU) with Aragen Life Sciences, a leading provider of R&D a...
WestGene Biopharma is proud to announce that its innovative mRNA therapeutic cancer vaccine, WGc-043, has received dual Investigational New Drug (IND) ap...
-Parse Biosciences, a leading provider of cost-effective and scalable solutions for single-cell sequencing, today announced an agreement with the Taiwane...
NEC Bio Therapeutics and AGC Biologics have announced a partnership to advance the production of NECVAX-NEO1, an orally delivered, bacteria...
Agreement builds on and complements Daiichi Sankyo and Merck’s shared commitment to develop novel medicines for patients with cancer Daiichi Sanky...
Advanced Clinical, a privately held clinical research services organization committed to providing a better clinical experience across the drug developme...
Inventiva , a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with met...
Valneva to receive up to $41.3 million from CEPI and the European Union to expand access to chikungunya vaccine, IXCHIQ® Funding will support clin...
GC Cell Corporation (hereinafter referred to as "GC Cell"; 144510:KOSDAQ) and Lukas Biomedical Co., Ltd. (hereinafter referred to as "Lukas," TWSE ...
Innovent Biologics, a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of on...
Shanghai Junshi Biosciences Co., a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercializati...
Collaboration explores the potential synergistic effects of Checkpoint’s anti-PD-L1, cosibelimab, in combination with the autologous T cell thera...
© 2025 Biopharma Boardroom. All Rights Reserved.
